Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19

NCT04902183 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Covid19

Interventions

DRUG: CovenD24

Sponsor

Athens Medical Society

Collaborators

[object Object]
[object Object]